Cardio Diagnostics Expands Provider Network with 15 New Partners

Cardio Diagnostics Holdings, Inc. has announced a significant expansion of its provider network, adding 15 new medical organizations from various regions across the United States. This move, which took place on October 21, 2025, underscores the growing adoption of the company’s advanced blood tests, Epi+Gen CHD™ and Precision CHD™, designed to enhance the prevention, detection, and management of coronary heart disease.

The newly partnered organizations represent a diverse array of medical specialties and care models, spanning four major regions: Northeast, South, Midwest, and West. By incorporating Cardio Diagnostics’ innovative testing technologies, these providers can gain valuable insights into coronary heart disease and heart attack risk, thereby facilitating more personalized treatment plans for their patients.

The addition of these 15 providers is a notable milestone in Cardio Diagnostics’ mission to broaden access to precision cardiovascular medicine. With cardiovascular disease on the rise, the company’s cutting-edge tools aim to address the needs of various patient demographics within different healthcare settings.

Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics, emphasized the importance of these partnerships, stating, “This expansion reflects the strong momentum we’re building in the provider community. These partnerships span an impressive range of care models, from concierge and functional medicine to direct primary care. By equipping these practices with our Epi+Gen CHD™ and Precision CHD™ tests, we’re not only enhancing patient care and driving better outcomes, but we’re also making Precision Cardiovascular Medicine accessible to more patients nationwide.”

Cardio Diagnostics’ solutions uniquely combine epigenetics, genetics, and artificial intelligence to deliver in-depth insights into heart attack risk and the underlying factors contributing to coronary heart disease. Given that coronary heart disease remains the leading cause of death globally, these tools play a critical role in both early detection and ongoing management across diverse patient populations and healthcare environments.

The company, which utilizes a proprietary AI-driven Integrated Genetic-Epigenetic Engine, aims to become a leader in the medical technology sector focused on improving the prevention, detection, and treatment of cardiovascular diseases. With an increasing number of healthcare providers adopting evidence-based practices to support cardiovascular health, the innovative tests from Cardio Diagnostics are proving to be essential resources for effective heart health management.

As the company continues to expand its reach, it is well-positioned to contribute to the evolving landscape of cardiovascular care, making significant strides towards more personalized and precise medical solutions. For further information about Cardio Diagnostics, interested parties can visit the company’s website at https://cdio.ai/.

This expansion aligns with the company’s strategic goals, reflecting its commitment to improving patient outcomes through innovative technology.